Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Non-alcoholic fatty liver disease and colorectal cancer survival.

Wu K, Zhai MZ, Weltzien EK, Cespedes Feliciano EM, Meyerhardt JA, Giovannucci E, Caan BJ.

Cancer Causes Control. 2019 Feb;30(2):165-168. doi: 10.1007/s10552-018-1095-z. Epub 2018 Nov 15.

2.

Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.

Gulbahce HE, Bernard PS, Weltzien EK, Factor RE, Kushi LH, Caan BJ, Sweeney C.

Cancer. 2018 Dec 15;124(24):4676-4684. doi: 10.1002/cncr.31776. Epub 2018 Oct 12.

PMID:
30311638
3.

Muscle radiodensity and mortality in patients with colorectal cancer.

Kroenke CH, Prado CM, Meyerhardt JA, Weltzien EK, Xiao J, Cespedes Feliciano EM, Caan BJ.

Cancer. 2018 Jul 15;124(14):3008-3015. doi: 10.1002/cncr.31405. Epub 2018 May 24.

4.

Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.

Caan BJ, Cespedes Feliciano EM, Prado CM, Alexeeff S, Kroenke CH, Bradshaw P, Quesenberry CP, Weltzien EK, Castillo AL, Olobatuyi TA, Chen WY.

JAMA Oncol. 2018 Jun 1;4(6):798-804. doi: 10.1001/jamaoncol.2018.0137.

5.

Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.

Cespedes Feliciano EM, Kwan ML, Kushi LH, Chen WY, Weltzien EK, Castillo AL, Sweeney C, Bernard PS, Caan BJ.

Cancer. 2017 Jul 1;123(13):2535-2542. doi: 10.1002/cncr.30637. Epub 2017 Mar 13.

6.

Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors.

Cespedes Feliciano EM, Kwan ML, Kushi LH, Weltzien EK, Castillo AL, Caan BJ.

Breast Cancer Res Treat. 2017 Apr;162(3):549-557. doi: 10.1007/s10549-017-4133-8. Epub 2017 Feb 7.

7.

Metabolic Dysfunction, Obesity, and Survival Among Patients With Early-Stage Colorectal Cancer.

Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Dannenberg AJ, Kwan ML, Xiao J, Quesenberry C, Weltzien EK, Castillo AL, Caan BJ.

J Clin Oncol. 2016 Oct 20;34(30):3664-3671. doi: 10.1200/JCO.2016.67.4473.

8.

Postdiagnosis Weight Change and Survival Following a Diagnosis of Early-Stage Breast Cancer.

Cespedes Feliciano EM, Kroenke CH, Bradshaw PT, Chen WY, Prado CM, Weltzien EK, Castillo AL, Caan BJ.

Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):44-50. doi: 10.1158/1055-9965.EPI-16-0150. Epub 2016 Aug 26.

9.

Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival.

Kwan ML, Bernard PS, Kroenke CH, Factor RE, Habel LA, Weltzien EK, Castillo A, Gunderson EP, Maxfield KS, Stijleman IJ, Langholz BM, Quesenberry CP Jr, Kushi LH, Sweeney C, Caan BJ.

J Natl Cancer Inst. 2015 Apr 28;107(7). pii: djv087. doi: 10.1093/jnci/djv087. Print 2015 Jul.

10.

Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.

Kwan ML, Kroenke CH, Sweeney C, Bernard PS, Weltzien EK, Castillo A, Factor RE, Maxfield KS, Stijleman IJ, Kushi LH, Quesenberry CP Jr, Habel LA, Caan BJ.

BMC Cancer. 2015 Apr 14;15:278. doi: 10.1186/s12885-015-1263-4.

11.

Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.

Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, Castillo A, Bernard PS, Factor RE, Kushi LH, Caan BJ.

Breast Cancer Res Treat. 2014 Apr;144(3):689-99. doi: 10.1007/s10549-014-2899-5. Epub 2014 Mar 7.

12.

Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.

Caan BJ, Sweeney C, Habel LA, Kwan ML, Kroenke CH, Weltzien EK, Quesenberry CP Jr, Castillo A, Factor RE, Kushi LH, Bernard PS.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):725-34. doi: 10.1158/1055-9965.EPI-13-1017. Epub 2014 Feb 12.

13.

Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.

Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr, Shakespear K, Weltzien EK, Stijleman IJ, Davis CA, Ebbert MT, Castillo A, Kushi LH, Caan BJ.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):714-24. doi: 10.1158/1055-9965.EPI-13-1023. Epub 2014 Feb 12.

14.

Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project.

Kwan ML, Chen WY, Flatt SW, Weltzien EK, Nechuta SJ, Poole EM, Holmes MD, Patterson RE, Shu XO, Pierce JP, Caan BJ.

Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):32-41. doi: 10.1158/1055-9965.EPI-12-1022. Epub 2012 Nov 13.

15.

Weight change and survival after breast cancer in the after breast cancer pooling project.

Caan BJ, Kwan ML, Shu XO, Pierce JP, Patterson RE, Nechuta SJ, Poole EM, Kroenke CH, Weltzien EK, Flatt SW, Quesenberry CP Jr, Holmes MD, Chen WY.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1260-71. doi: 10.1158/1055-9965.EPI-12-0306. Epub 2012 Jun 13. Erratum in: Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):319.

16.

Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project.

Kwan ML, Chen WY, Kroenke CH, Weltzien EK, Beasley JM, Nechuta SJ, Poole EM, Lu W, Holmes MD, Quesenberry CP Jr, Pierce JP, Shu XO, Caan BJ.

Breast Cancer Res Treat. 2012 Apr;132(2):729-39. doi: 10.1007/s10549-011-1914-3. Epub 2011 Dec 21.

17.

Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project.

Beasley JM, Kwan ML, Chen WY, Weltzien EK, Kroenke CH, Lu W, Nechuta SJ, Cadmus-Bertram L, Patterson RE, Sternfeld B, Shu XO, Pierce JP, Caan BJ.

Breast Cancer Res Treat. 2012 Jan;131(2):637-43. doi: 10.1007/s10549-011-1770-1. Epub 2011 Sep 21.

18.

Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort.

Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW.

Breast Cancer Res Treat. 2011 Sep;129(2):549-56. doi: 10.1007/s10549-011-1505-3. Epub 2011 Apr 11.

19.

Long-term prognostic role of functional limitations among women with breast cancer.

Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, Moore DH, Slattery ML, Tammemagi M, Castillo A, Melisko M, Esserman L, Weltzien EK, Caan BJ.

J Natl Cancer Inst. 2010 Oct 6;102(19):1468-77. doi: 10.1093/jnci/djq344. Epub 2010 Sep 22.

20.

Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study.

Guha N, Kwan ML, Quesenberry CP Jr, Weltzien EK, Castillo AL, Caan BJ.

Breast Cancer Res Treat. 2009 Nov;118(2):395-405. doi: 10.1007/s10549-009-0321-5. Epub 2009 Feb 17.

21.

Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A.

Sears C, Guydish JR, Weltzien EK, Lum PJ.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):193-201.

PMID:
11404542

Supplemental Content

Loading ...
Support Center